First-of-its-Kind cell therapy tested for debilitating muscle disease
NCT ID NCT07058298
Summary
This is a very early study testing a new type of treatment called GC012F, a CAR-T cell therapy, for people with severe myasthenia gravis that hasn't responded to standard treatments. The main goals are to check if the treatment is safe and to look for early signs that it might help control the disease. About 6 participants will have their own immune cells collected, modified in a lab, and then infused back to try to reset their immune system.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS (GMG) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital of Tongji Medical Colledge, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact
Conditions
Explore the condition pages connected to this study.